found that induction of P-Rex1 promoted Rac1-mediated ERK activation that was associated with resistance to anti-vascular endothelial growth factor (VEGF)/anti-vascular endothelial growth factor receptor (VEGFR) therapies in prostate cancer (44). Here, RAC1 is linked to prostate cancer.